To investigate clinical efficacy of the high dose dexamethasone (HD-DXM) combined with recombinant human interleukin-11 (rhIL-11) in the treatment of the adult patients with newly diagnosed primary immune thrombocytopenia (ITP).
The medical records of 47 newly diagnosed primary ITP patients with bleeding symptoms or risks, who received HD-DXM alone or in combination with rhIL-11, were retrospectively identified and systemically analyzed. These patients were divided into four groups according to their bleeding scale prior to initiation of treatment and therapeutic schedules, including monotherapy group (dexamethasone 40 mg/d on days 1-4) and combination therapy group [dexamethasone 40 mg/d on days 1-4 combined with rhIL-11 25 μg/(kg·d) on days 1-7] as well as high-risk group (bleeding scores≥5) and low-risk group (bleeding scores < 5). The clinical efficacy, onset time of response, duration of response, the platelet recovery level and treatment related toxicity profiles among different groups were systematically analyzed and compared.
The platelet recovery level and duration of response in combination therapy group were more pronounced than those in monotherapy group [(97.38±49.18)×109/L vs (158.72±41.72)×109/L and (18.15±4.54) d vs (12.43±3.18) d, P < 0.01]. The rates of complete response (CR), response (R), no response (NR) and relapse as well as onset time of response showed no statistical difference between combination and monotherapy groups (P>0.05). Furthermore, the CR rate and platelet recovery level as well as duration of response in the ITP patients with high bleeding scores in combination therapy group was significantly higher than those in monotherapy group [37.50% vs 21.74%, (226.75±52.68)×109/L vs (166.72±39.28)×109/L and (18.45±4.48) d vs (11.84±3.73) d, P<0.01]. Meanwhile, the rates of R, NR and relapse as well as onset time of response in high bleeding scores patients were shown little difference between combination therapy and monotherapy group (P>0.05). The platelet recovery level as well as duration of response in ITP patients with low bleeding scores in combination group were significantly higher than those in monotherapy group [(184.36±44.50)×109/L vs (148.48±46.37)×109/L and (17.72±3.32) d vs (14.52±4.18) d, P<0.05]. In addition, the rates of CR, R, NR and relapse as well as onset time of response in ITP patients with low bleeding scores were shown little difference between combination and monotherapy group (P>0.05). Concerning treatment related toxicity profiles, no grade 3~4 toxicity occurred in patients of combination and monotherapy group.
HD-DXM combined with rhIL-11 is an effective and well tolerated therapeutic approach for the adult patients with newly diagnosed primary ITP. It can increase the platelet recovery level and improve response duration as well as clinical efficacies in the patients with high bleeding risk, which serves as a platform for the design of future prospective clinical trials.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |